Functional genomics identifies new synergistic therapies for retinoblastoma
Open Access
- 30 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 39 (31), 5338-5357
- https://doi.org/10.1038/s41388-020-1372-7
Abstract
Local intravitreal or intra-arterial chemotherapy has improved therapeutic success for the pediatric cancer retinoblastoma (RB), but toxicity remains a major caveat. RB initiates primarily withRB1loss or, rarely,MYCNamplification, but the critical downstream networks are incompletely understood. We set out to uncover perturbed molecular hubs, identify synergistic drug combinations to target these vulnerabilities, and expose and overcome drug resistance. We applied dynamic transcriptomic analysis to identify network hubs perturbed in RB versus normal fetal retina, and performed in vivo RNAi screens inRB1(null)andRB1(wt);MYCN(amp)orthotopic xenografts to pinpoint essential hubs. We employed in vitro and in vivo studies to validate hits, define mechanism, develop new therapeutic modalities, and understand drug resistance. We identified BRCA1 and RAD51 as essential for RB cell survival. Their oncogenic activity was independent of BRCA1 functions in centrosome, heterochromatin, or ROS regulation, and instead linked to DNA repair. RAD51 depletion or inhibition with the small molecule inhibitor, B02, killed RB cells in a Chk1/Chk2/p53-dependent manner. B02 further synergized with clinically relevant topotecan (TPT) to engage this pathway, activating p53-BAX mediated killing of RB but not human retinal progenitor cells. Paradoxically, a B02/TPT-resistant tumor exhibited more DNA damage than sensitive RB cells. Resistance reflected dominance of the p53-p21 axis, which mediated cell cycle arrest instead of death. Deleting p21 or applying the BCL2/BCL2L1 inhibitor Navitoclax re-engaged the p53-BAX axis, and synergized with B02, TPT or both to override resistance. These data expose new synergistic therapies to trigger p53-induced killing in diverse RB subtypes.This publication has 81 references indexed in Scilit:
- Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma developmentBMC Cancer, 2012
- Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiationOncogene, 2012
- BRCA1 tumour suppression occurs via heterochromatin-mediated silencingNature, 2011
- The TAg-RB Murine Retinoblastoma Cell of Origin Has Immunohistochemical Features of Differentiated Müller Glia with Progenitor PropertiesInvestigative Ophthalmology & Visual Science, 2011
- Identification of Specific Inhibitors of Human RAD51 Recombinase Using High-Throughput ScreeningACS Chemical Biology, 2011
- High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencingGenome Biology, 2011
- Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− miceNature Genetics, 2009
- Division and apoptosis of E2f-deficient retinal progenitorsNature, 2009
- p21 in cancer: intricate networks and multiple activitiesNature Reviews Cancer, 2009
- Genomic Analysis of Mouse Retinal DevelopmentPLoS Biology, 2004